November 1, 2018 7:11pm
Sentiment is bubbling enhanced by trading of the oversold, fundamentals are improving and risks are being mitigated so far by quarterly results in some cases
Pre-open indications: 1 HIT and 2 MISS
I’ll take a slap on the wrist for my forecast miss on NTLA on earnings and a trial delay but, they are seeing a high that will dissipate – the trust factor of communication still smacks of deception!
Quarterly results: bluebird bio (BLUE) reported a loss of -$145.5 M or -$2.73 per share as compared to Q3/17’s $78.8 M or -$1.73. Revenue was $11.5 M. Cash as of 9/30/18 were $2 B compared to $100.9 M as of 12/31/17. Fate Therapeutics (FATE) reported a net loss of $16.76 M or -$0.31 per share as compared to Q3/17’s $10.6 M or -$0.26. Revenue was $1 M. Cash as of 9/30/18 were $211.2 M compared to $100.9 M as of 12/31/17. Interesting balance sheet number, accounts payable and accrued expenses = 14.97 M.
Who is defining the metrics for individual investors?
The next few trading sessions will be critical for the RegMed sector which will establish whether market reaction this month is temporary and short-lived, or if this is the start of a more fundamental correction.
Members only. Please login.